

Assembly Biosciences to Participate in Jefferies 2018 Global Healthcare Conference

June 4, 2018

INDIANAPOLIS and SAN FRANCISCO, June 04, 2018 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral synthetic live biotherapeutics for disorders associated with the microbiome, today announced that Richard Colonno, PhD, Assembly's executive vice president and chief scientific officer of virology operations, will participate in a fireside chat at the Jefferies 2018 Global Healthcare Conference at 10:00 a.m ET on Wednesday, June 6, 2018. The conference is being held in New York City.

A live audio webcast of the fireside chat will be available at investor.assemblybio.com, and a replay will be available for approximately 30 days.

About Assembly Biosciences

Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral synthetic live biotherapeutics for disorders associated with the microbiome. Assembly's HBV-cure program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. TAssembly's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patented delivery system, GEMICEL[®], which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. For more information, visit assemblybio.com.

Contacts

Assembly Biosciences, Inc.

Investors: Lauren Glaser (415) 521-3828 Iglaser@assemblybio.com

Primary Logo

Source: Assembly Biosciences